Levitte Steven, Ganguly Abantika, Frolik Sophie, Guevara-Tique Alix A, Patel Shaini, Tadas Ann, Klein Orly, Shyr David, Agarwal-Hashmi Rajni, Beach Lynn, Callard Elizabeth, Weinacht Katja, Bertaina Alice, Thakor Avnesh S
Interventional Radiology Innovation at Stanford (IRIS), 3155 Porter Drive, Palo Alto, CA 94304, USA.
Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Stanford University, Palo Alto, CA 94304, USA.
J Clin Med. 2023 Jun 23;12(13):4229. doi: 10.3390/jcm12134229.
Graft versus host disease (GVHD) is one of the most serious complications following stem cell transplant in children and is a major cause of morbidity and mortality. Corticosteroids remain the mainstay of treatment, and although a majority of children respond to systemic steroids, those refractory to or dependent upon corticosteroids suffer from complications secondary to long-term steroid administration. This problem has prompted consideration of steroid-sparing treatment strategies, although the time to clinical remission can be variable. Intraarterial corticosteroid delivery has been used in adults as a rescue therapy in steroid-resistant patients, but its use in children has been limited. We investigated the feasibility of intraarterial steroid administration into the bowel and/or liver in a cohort of six pediatric patients with acute GVHD. All patients successfully underwent treatment with no serious adverse effects. Five of five (100%) patients with gastrointestinal bleeding due to GVHD had rapid symptom improvement by 48 h, which was durable up to three weeks. Three of four (75%) patients with hepatic GVHD had improved cholestasis following intraarterial steroid administration. Our experience with this small cohort preliminarily demonstrated the feasibility and safety of intraarterial steroid administration in children with acute GVHD. This approach warrants consideration as a rescue therapy in steroid-refractory cases and as a "bridge" therapy for children with severe acute GVHD who are transitioning to steroid-sparing regimens.
移植物抗宿主病(GVHD)是儿童干细胞移植后最严重的并发症之一,也是发病和死亡的主要原因。皮质类固醇仍然是主要的治疗方法,虽然大多数儿童对全身用类固醇有反应,但那些对皮质类固醇难治或依赖的儿童会因长期使用类固醇而出现并发症。这个问题促使人们考虑采用节省类固醇的治疗策略,尽管临床缓解时间可能各不相同。动脉内给予皮质类固醇已在成人中用作类固醇抵抗患者的挽救治疗,但在儿童中的应用有限。我们调查了在一组6例急性GVHD儿科患者中,向肠道和/或肝脏动脉内给予类固醇的可行性。所有患者均成功接受治疗,无严重不良反应。5例因GVHD导致胃肠道出血的患者中有5例(100%)在48小时内症状迅速改善,且持续长达三周。4例肝GVHD患者中有3例(75%)在动脉内给予类固醇后胆汁淤积有所改善。我们对这个小队列的经验初步证明了动脉内给予类固醇在急性GVHD儿童中的可行性和安全性。这种方法值得作为类固醇难治病例的挽救治疗以及作为正在过渡到节省类固醇方案的重度急性GVHD儿童的“桥梁”治疗加以考虑。